Simlandi launches in U.S. as third interchangeable Humira biosimilar
Click Here to Manage Email Alerts
Key takeaways:
- Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a high-concentration.
- Simlandi is indicated for many chronic autoimmune conditions.
Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.
As Healio previously reported, Simlandi (adalimumab-ryvk) was approved in February as the first interchangeable, citrate-free Humira (adalimumab, AbbVie) biosimilar to be available in a high-concentration formulation for the treatment of adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis as well as Crohn’s disease and juvenile idiopathic arthritis.
“We are proud to make Simlandi available in the U.S. to patients and providers,” Thomas Rainey, senior vice president of U.S. market access at Teva, said in the release. “Biosimilars create opportunities for cost savings across the healthcare system, and Simlandi’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. market.”
With nearly 88% of U.S. prescriptions for adalimumab being for the high-concentration as opposed to the low-concentration presentation, the companies anticipate the market will see Simlandi as an important contributor.
According to the press release, Teva and Alvotech will be working with payors to ensure access to Simlandi in addition to six other biosimilars that are poised to hit the market in 2027.
Click Here to Manage Email Alerts